伏妥珠單抗
伏妥珠單抗（INN：flotetuzumab[1]；開發代號：MGD006）是一種雙特異性抗體，[2]設計用於治療急性骨髓性白血病。[3][4]該藥物由MacroGenics公司開發。[5]
| 單克隆抗體 | |
|---|---|
| 種類 | 雙單鏈可變區片段 |
| 目標 | CD3、CD123 |
| 臨床資料 | |
| 其他名稱 | MGD006 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1664355-28-5 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C2618H4040N704O813S16 |
| 摩爾質量 | 58,898.19 g·mol−1 |
參考資料
編輯- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118 (PDF). WHO Drug Information. 2017, 31 (4) [2024-03-12]. （原始內容存檔 (PDF)於2020-08-15）.
- ^ Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Hematol Malig Rep. October 2018, 13 (6): 417–425. PMC 6295344
. PMID 30280288. doi:10.1007/s11899-018-0472-8.
- ^ Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE. Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity. Clin. Cancer Res. June 2018, 24 (11): 2631–2641. PMID 29463552. doi:10.1158/1078-0432.CCR-17-2265 ..
- ^ Assi R, Kantarjian H, Ravandi F, Daver N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr. Opin. Hematol. March 2018, 25 (2): 136–145. PMID 29206680. S2CID 23901088. doi:10.1097/MOH.0000000000000401.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Flotetuzumab （頁面存檔備份，存於網際網路檔案館）, American Medical Association.
